

AMENDMENTS TO THE CLAIMS:

Please amend claims 1 and 7, and cancel claims 8-10 without prejudice or disclaimer as follows. This listing of claims replaces all prior versions, and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently amended) A method for the treatment of gastrointestinal tumors, ~~whose growth is stimulated by glycine-extended gastrin-17~~, comprising: administering to a mammal a therapeutically effective amount of an anti-G17 immunogenic composition, wherein:
the gastrointestinal tumor expresses glycine-extended gastrin-17; and
the amount of the immunogenic composition administered is sufficient to induce an anti-gastrin-17 antibody titer to neutralize inhibit physiological effects of gastrin-17, amidated gastrin and glycine-extended gastrin-17.
2. Cancelled.
3. (Original) The method of claim 1, wherein the gastrointestinal tumors contain gastrin/cholecystokinin B (CCK-B) receptors.
4. (Original) The method of claim 1, wherein the gastrointestinal tumors are colorectal adenocarcinomas.
5. (Original) The method of claim 1, wherein the mammal is a human.
6. (Withdrawn) The method of claim 1, further comprising:
assaying a serum sample from the mammal to determine the level of extended gastrin 17 to determine a dosage of the composition for neutralization of gastrin-17 and glycine- extended gastrin-17 to inhibit growth of tumor cells.
7. (Withdrawn, Currently Amended) The method of claim 1, further comprising:
monitoring antibody titer levels against glycine-extended glycine-17 ~~and amidated glycine-17~~; and
administering booster immunizations of the immunogenic composition to maintain an antibody titer effective to neutralize glycine-extended glycine-17 and amidated glycine-17.
8. -10. Cancelled.